Skip to main content
OpenTrials
Completed

NCT Number: NCT01105481

Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients

This study includes two main components: the first screening phase and the second clinical intervention phase. During the screening phase, subjects with poor response to clozapine are carefully evaluated by chart-review and clinical assessment. Via chart-review, clinical data of diagnosis, disease course and previous treatment outcome, and concomitant psychotropic agents are obtained. Clinical phenomenology, including psychopathology, psychotic and mood symptoms severity and side effect of psychotropic medication are assessed by clinical interview and observation, which are conducted by experienced clinicians. Blood sample will be also obtained from the subjects for measuring the baseline clozapine drug level and extracting DNA for further analysis. Subjects fulfilling the criteria of treatment-resistant schizophrenia with poor response to adequate dose and duration of clozapine treatment are eligible for the clinical trial phase of 14-week randomized, placebo-controlled amisulpride add-on study. In this phase, subjects are randomly allocated to amisulpride augmentation treatment group and placebo treatment group. Subjects in the former group will receive clozapine and amisulpride combination treatment, while in the latter group will receive clozapine and placebo. Outcomes of clinical efficacy and safety are carefully evaluated by experienced and well-trained research stuffs in the 14 weeks of clinical study period.

All of the above studies will be conducted in four hospitals, including DOH Bali Psychiatric Hospital, DOH Tao-yan Psychiatric hospital, and the Ju-Shang Psychiatric Hospital. Subjects will be recruited from the chronic in-patient settings from these three hospitals.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Treatment-resistant Schizophrenia Mental Disorders Schizophrenia Schizophrenia Spectrum and Other Psychotic Disorders Schizophrenia, Treatment-Resistant

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Bali Psychiatric Center, Taipei County, Taiwan

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • DSM-IV diagnosed schizophrenic patients;
  • Age between 18 and 60;
  • Before treatment with clozapine, documented treatment failure of two antipsychotics for an adequate duration of 6 weeks and in a sufficient dose of 600 mg/day of chlorpromazine equivalents;
  • Documented failure to show a satisfactory clinical response to an adequate clozapine treatment, defined as at least clozapine 300 mg/day for 3 months or a plasma drug level of 350ng/ml;
  • At least moderately ill, defined as with a Clinical Global Impression (CGI) greater than 4 or PANSS total score greater than 75;
  • Persistent positive psychotic symptoms, with rating scores of moderate or worse on at least two of four positive symptom items (delusion, conceptual disorganization, hallucinatory behavior, and suspiciousness/persecution) on Positive and Negative Syndrome Scale (PANSS);

Exclusion criteria

  • Patients with concomitant treatment with lithium, anti-convulsants, antidepressants and other antipsychotic medication ;
  • Patients with underlying severe medical illness, such as cardiovascular disease, cerebrovascular disease, bone marrow suppression or epilepsy;
  • Patients with comorbid diagnosis of substance dependence;

Treatment and study plan

Amisulpride add-on

Drug

At the beginning of the treatment phase (day 1), subjects in the combination treatment group will be started with adjunctive amisulpride, with a starting dose of 200 mg per day. Amisulpride is planned to increase to 400 mg/day on day 8, 600mg/day on day 15 and 800 mg/day on day 22, according to the subjects' responses and tolerability. All of the add-on amisulpride will be provided to subjects at night. To permit dose adjustment and ensure double-blind procedure, 200mg amisulpride is packed in capsules identical to those used for the placebo.

Placebo add-on

Drug

For subjects randomly allocated to the placebo treatment group, they will be added with one capsule of placebo from Day 1. On Day 8, Day 15 and Day 22, the placebo will be increased to 2, 3 and 4 capsules, respectively. and adjunctive amisulpride, with a starting dose of 200 mg per day. Amisulpride is planned to increase to 400 mg/day on day 8, 600mg/day on day 15 and 800 mg/day on day 22, according to the subjects' responses and tolerability. To permit dose adjustment and ensure double-blind procedure, 200mg amisulpride is packed in capsules identical to those used for the placebo.

Primary outcomes

  1. Positive and Negative Symptom Scale(PANSS) total score change

    Time frame: 12 wks after treatment

    The change from baseline of the Positive and Negative Symptom Scale (PANSS) total score.

Secondary outcomes

  1. Positive and Negative Symptom Scale (PANSS) positive-symptom subscale score

    Time frame: 12 wks after treatment

    The change from baseline of the Positive and Negative Symptom Scale (PANSS) positive-symptom subscale score (sum of item P1 to P7)

  2. Positive and Negative Symptom Scale (PANSS) negative-symptom subscale score

    Time frame: 12 wks after treatment

    The change from baseline of the Positive and Negative Symptom Scale (PANSS) negative-symptom subscale score (sum of item N1 to N7)

  3. Positive and Negative Symptom Scale (PANSS) general psychopathology score

    Time frame: 12 wks after treatment

    The change from baseline of the Positive and Negative Symptom Scale (PANSS) general psychopathology subscale score (sum of item G1 to G14)

  4. Clinical Global Impressions (CGI) scale score

    Time frame: 12 wks after treatment

    The change from baseline of the Clinical Global Impressions (CGI) scale score

  5. Brief Psychotic Rating Scale (BPRS) total score

    Time frame: 12 wks after treatment

    The change from baseline of the Brief Psychotic Rating Scale (BPRS) score

Sponsors and collaborators

Lead sponsor

National Health Research Institutes, Taiwan

Other

Registry information

Official study title

Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients: A 14-week Randomized, Double-blind and Placebo-controlled Trial

Acronym: M1106

Important dates

Study start
2006
Primary completion
2008
Study completion
2008
First posted
Apr 16, 2010
Registry last updated
Apr 16, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.